Definitive Healthcare Corp (DH)
NASDAQ:DH
Want to see DH full AI Analyst Report?
Top Page
Definitive Healthcare Corp
(NASDAQ:DH)
Select Model
Select Model
Rating:49Neutral
Price Target:
$0.80
▼(-22.04% Downside)
Action:Reiterated
Date:05/09/26
DH scores below average primarily due to contracting revenue and ongoing GAAP losses, reinforced by weak technicals (below key moving averages with negative momentum). The score is partially supported by conservative leverage and positive free cash flow, plus earnings-call evidence of margin improvement and maintained/raised profitability outlook, but continued top-line declines and reduced RPO/deferred revenue limit confidence.
Positive Factors
High Gross Margins
Sustained ~76–81% gross margins indicate strong unit economics and pricing power in its data/analytics business. High gross margin creates room to invest in R&D, integrations and sales while operational improvements can translate to durable operating leverage as revenue stabilizes.
Negative Factors
Contracting Revenue
Sustained top-line declines weaken scale economics, limit margins expansion and raise execution risk for turning improvements in product and operations into growth. Persistent revenue contraction pressures visibility, compensation models and long-term unit economics.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margins
Sustained ~76–81% gross margins indicate strong unit economics and pricing power in its data/analytics business. High gross margin creates room to invest in R&D, integrations and sales while operational improvements can translate to durable operating leverage as revenue stabilizes.
Read all positive factors
Definitive Healthcare Corp (DH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$120.84M
Dividend YieldN/A
Average Volume (3M)338.90K
Price to Earnings (P/E)―
Beta (1Y)1.59
Revenue Growth-3.89%
EPS Growth63.03%
CountryUS
Employees782
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-1.62
Shares Outstanding105,524,240
10 Day Avg. Volume311,870
30 Day Avg. Volume338,897
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.09
Price to Sales (P/S)1.27
P/FCF Ratio8.26
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue0.44
Enterprise Value/Gross Profit0.60
Enterprise Value/Ebitda8.97
Forecast
1Y Price Target
$2.51Price Target Upside144.11% Upside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)0.18
Revenue Forecast (FY)$223.61M
Definitive Healthcare Corp Business Overview & Revenue Model
Company Description
Definitive Healthcare Corp., together with its subsidiaries, provides healthcare commercial intelligence in the United States. Its solutions provide information on healthcare providers and their activities to help its customers in the area ranging...
How the Company Makes Money
Definitive Healthcare primarily makes money by selling access to its healthcare commercial intelligence offerings on a subscription basis, with customers paying recurring fees to use its software platform and datasets for sales, marketing, and str...
Definitive Healthcare Corp Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 12, 2026
Earnings Call Sentiment Neutral
The call presents a mixed but constructive picture: near-term top-line pressures persist, driven by the life sciences segment and a shift to shorter-duration deals (reflected in declines in revenue, deferred revenue, and RPO). Offsetting these headwinds are stronger-than-expected profitability and margin expansion, solid cash generation (~$50M trailing FCF), meaningful operational progress on data quality (claims remediation), faster and more numerous integrations, professional services acceleration (+25% YoY), and a clear AI/innovation roadmap that management expects will drive improved retention and future monetization. The company beat guidance on profit metrics and is maintaining full-year targets while investing in strategic initiatives to return to growth, but material execution is still required to translate operational improvements into sustained top-line growth.Positive Updates
Revenue Performance vs Guidance
Reported total revenue of $55.9M, which was at the high end of guidance despite a 6% year-over-year decline; Q1 performance and beat on guidance support the company’s full-year targets.
Negative Updates
Top-Line Declines and Forward Guidance
Q1 revenue down 6% YoY; Q2 guidance of $55M–$56M implies an 8%–9% YoY decline; full-year 2026 revenue guidance of $220M–$226M implies a 6%–9% YoY decline, indicating continued top-line pressure.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue Performance vs Guidance
Reported total revenue of $55.9M, which was at the high end of guidance despite a 6% year-over-year decline; Q1 performance and beat on guidance support the company’s full-year targets.
Read all positive updates
Company Guidance
For Q2 2026 the company guided revenue of $55.0–56.0 million (down 8%–9% YoY), adjusted operating income of $10.5–11.5 million, adjusted EBITDA of $13.0–14.5 million (24%–26% margin), adjusted net income of $5.0–6.0 million (~$0.03–0.04 per diluted share on ~144.2 million weighted average shares), and reiterated expectations for continued double‑digit professional services growth; for full‑year 2026 they reiterated revenue guidance of $220–226 million (down 6%–9% YoY), adjusted operating income of $43.5–47.5 million, adjusted EBITDA of $55–59 million (25%–26% margin, with a $1.5 million midpoint increase vs. prior guide), adjusted net income of $23–27 million (~$0.16–0.19 per share on ~144.9 million weighted shares), while noting higher capitalized software development (nearly $3 million in Q1) and that Q1 results (revenue $55.9M, adj. EBITDA $15.3M, 27% margin, adj. EPS $0.06) were at or above the high end of quarterly guidance, supporting the full‑year targets.Definitive Healthcare Corp Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
63
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 238.26M | 241.52M | 252.20M | 251.41M | 222.65M | 166.15M |
| Gross Profit | 172.84M | 183.28M | 197.47M | 203.93M | 180.03M | 125.47M |
| EBITDA | 11.60M | -162.15M | -567.24M | -241.23M | 26.23M | 23.08M |
| Net Income | -170.32M | -138.93M | -413.12M | -202.39M | -7.22M | -51.91M |
Balance Sheet | ||||||
| Total Assets | 514.74M | 735.49M | 1.09B | 1.83B | 2.12B | 2.12B |
| Cash, Cash Equivalents and Short-Term Investments | 178.09M | 180.89M | 290.16M | 308.07M | 331.87M | 387.50M |
| Total Debt | 169.84M | 177.82M | 253.11M | 267.93M | 275.85M | 270.68M |
| Total Liabilities | 324.04M | 356.50M | 482.19M | 626.73M | 640.68M | 617.78M |
| Stockholders Equity | 146.23M | 281.11M | 444.38M | 861.36M | 948.92M | 871.31M |
Cash Flow | ||||||
| Free Cash Flow | 37.06M | 37.06M | 45.85M | 38.21M | 27.25M | 18.48M |
| Operating Cash Flow | 39.27M | 53.78M | 58.20M | 41.19M | 35.58M | 25.21M |
| Investing Cash Flow | 64.11M | 153.88M | -26.41M | -31.78M | -248.90M | -46.73M |
| Financing Cash Flow | -51.96M | -150.79M | -56.75M | -25.58M | -26.70M | 384.37M |
Definitive Healthcare Corp Technical Analysis
Negative
1.03
Price Trends
1.03
Negative
1.53
Negative
2.40
Negative
Market Momentum
-0.06
Positive
40.33
Neutral
13.58
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DH, the sentiment is Negative. The current price of 1.03 is above the 20-day moving average (MA) of 0.95, below the 50-day MA of 1.03, and below the 200-day MA of 2.40, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 40.33 is Neutral, neither overbought nor oversold. The STOCH value of 13.58 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DH.
Definitive Healthcare Corp Risk Analysis
Definitive Healthcare Corp disclosed 71 risk factors in its most recent earnings report. Definitive Healthcare Corp reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Definitive Healthcare Corp Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $694.15M | 25.74 | 5.67% | 0.52% | 6.64% | 6.54% | |
72 Outperform | $846.69M | 142.74 | 3.31% | ― | -1.19% | -21.87% | |
57 Neutral | $560.91M | 347.91 | 0.75% | ― | 14.48% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $438.68M | -2.40 | -77.89% | ― | -21.26% | -290.08% | |
49 Neutral | $120.84M | -0.23 | -67.07% | ― | -3.89% | 63.03% |
* Healthcare Sector Average
DH
Definitive Healthcare Corp
0.87
-2.27
-72.26%
HSTM
HealthStream
24.43
-3.65
-13.01%
EVH
Evolent Health
3.89
-4.11
-51.37%
PHR
Phreesia
9.17
-15.32
-62.56%
GDRX
GoodRx Holdings
2.52
-1.27
-33.51%
Definitive Healthcare Corp Corporate Events
Business Operations and StrategyExecutive/Board Changes
Definitive Healthcare Ends Spectrum Nomination Rights Agreement
Neutral
Apr 9, 2026
On March 30, 2026, Jeff Haywood, who had been designated to Definitive Healthcare Corp.’s board by private equity affiliate SE VII DHC AIV, L.P., resigned from the company’s board of directors, ending Spectrum’s direct representa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.